|Bid||43.15 x 900|
|Ask||45.11 x 1200|
|Day's range||38.52 - 45.62|
|52-week range||25.31 - 141.01|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||25 Feb 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||80.20|
Last year, Vir Biotechnology (NASDAQ: VIR) and GlaxoSmithKline (NYSE: GSK) partnered up to develop Vir's coronavirus antibody treatment. The London-based pharma must have liked what it saw in Vir, because GlaxoSmithKline recently signed on to develop more drugs developed by Vir. In this video from Motley Fool Live, recorded on Feb. 22, Fool.com contributors Brian Orelli and Keith Speights discuss the deal, which covers treatments and preventions for the flu and other viral infections, and what it means for Vir's future.
The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Regeneron (REGN), Vir (VIR) and KemPharm, Inc. (KMPH).
Shares of Vir Biotechnology (NASDAQ: VIR) are dropping sharply on Thursday despite the drugmaker not reporting any news. Goldman Sachs analyst Paul Choi lowered his price target on Vir Biotechnology from $61 to $59. As a reminder, Vir Biotechnology and its partner GlaxoSmithKline are taking part in the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Program, an initiative led by the U.S. National Institutes of Health (NIH).